




A




B



C



D



Supplementary Figure S3. Results from the second recurring tumor. **A.** Freshly sorted CD19-negative cells did not express *CD19* mRNA as assessed by qRT-PCR. **B.** Alternative splicing is likely not driving the antigen-negative escape in the assessed sample. Arrows are indicating the expected size of full length (FL; green) or truncated cDNA product (red), which was described by Sotillo *et al.* 2015. **C.** Bisulfite sequencing of a region spanning *CD19* promoter including 8 CpG sites in sorted CD19-negative and CD19-positive cells. X - not possible to evaluate. **D.** Freshly sorted CD19-negative cells from the second recurring tumor were treated with 5-aza-2'-deoxycytidine (AZA; 1 μM or 5 μM) or DMSO (CTRL) for 48h. Then, CD19 expression levels were assessed by flow cytometry.